Key result
Elevated low-attenuation non-calcified plaque burden on CCTA is linked to higher major event risk.
Why the study?
Low-attenuation plaque burden and PCAT inflammation predict cardiovascular outcomes, but their relationships with cardiometabolic risk factors such as lipoprotein(a) and epicardial adipose tissue required investigation.
Cohort (n=364)
p-value: p=<0.001
Elevated low-attenuation non-calcified plaque burden on CCTA, but not PCAT attenuation, is a significant predictor of adverse cardiovascular outcomes in a diverse patient population with stable chest pain.
May aid CCTA risk stratification in stable chest pain; extends plaque quantification data but requires prospective validation.
Introduction: Low-attenuation non-calcified plaque (LAP) burden and vascular inflammation by pericoronary adipose tissue (PCAT) measured from coronary CT angiography (CCTA) have shown to be predictors of cardiovascular outcomes. We aimed to investigate the relationships of cardiometabolic risk factors including lipoprotein(a) and epicardial adipose tissue (EAT) with CCTA high-risk imaging biomarkers, LAP and vascular inflammation. Methods: The patient population consisted of consecutive patients who underwent CCTA for stable chest pain and had a complete cardiometabolic panel including lipoprotein(a). Plaque, PCAT and EAT were measured from CT using semiautomated software. Elevated LAP burden and PCAT attenuation were defined as ≥4% and ≥70.5 HU, respectively. The primary clinical end-point was a composite of myocardial infarction, revascularization or cardiovascular death. Results: A total of 364 consecutive patients were included (median age 56 years, 64% female); the majority of patients were of Hispanic (60%), and the rest were of non-Hispanic Black (21%), non-Hispanic White (6%) and non-Hispanic Asian (4%) race/ethnicity. The prevalence of elevated LAP burden and PCAT attenuation was 31 and 18%, respectively, while only 8% had obstructive stenosis. There were significant differences in plaque characteristics among different racial/ethnic groups (p<0.001). Lipoprotein(a) correlated with LAP burden in Hispanic patients. Patients with elevated LAP were older, more likely to be have diabetes, hypertension, hyperlipidemia and smoke with higher CAC and EAT volume (all P<0.05). Patients with elevated LAP were more likely to develop the primary clinical outcome (p<0.001) but those with elevated PCAT were not (p=0.797). Conclusion: The prevalence of LAP and PCAT attenuation were 31 and 18%, respectively. Lipoprotein(a) levels correlated with LAP burden in Hispanic patients. Age, male sex, hypertension and hyperlipidemia increased the odds of elevated LAP, which showed prognostic significance.
No takes yet. Share an insight, caveat, or question.
Kuno et al. (2023) conducted a cohort in Stable chest pain (n=364). Elevated low-attenuation non-calcified plaque (LAP) burden vs. Non-elevated LAP burden was evaluated on Composite of myocardial infarction, revascularization or cardiovascular death (p=<0.001). Elevated low-attenuation non-calcified plaque burden on CCTA was significantly associated with a higher risk of myocardial infarction, revascularization, or cardiovascular death (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: